H
Hiroyuki Okuda
Researcher at Sapporo Medical University
Publications - 57
Citations - 880
Hiroyuki Okuda is an academic researcher from Sapporo Medical University. The author has contributed to research in topics: Colorectal cancer & Irinotecan. The author has an hindex of 12, co-authored 57 publications receiving 735 citations.
Papers
More filters
Journal ArticleDOI
Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells
Atsushi Yawata,Masaaki Adachi,Hiroyuki Okuda,Yasuyoshi Naishiro,Takenori Takamura,Masato Hareyama,Shinichi Takayama,John C. Reed,Kohzoh Imai +8 more
TL;DR: Gene transfer-mediated overexpression of Bcl-2 or BAG-1 led to prolonged cell survival of MKN74 cells against serum-starved apoptosis and anoikis, demonstrating that resistance to apoptosis is a crucial factor for development of peritoneal dissemination of human gastric cancer cells.
Journal ArticleDOI
Factors Associated With Risk for Colorectal Cancer Recurrence After Endoscopic Resection of T1 Tumors
Shinji Yoshii,Masanori Nojima,Masanori Nojima,Katsuhiko Nosho,Saori Omori,Takaya Kusumi,Hiroyuki Okuda,Hiroyuki Tsukagoshi,Masahiro Fujita,Hiroyuki Yamamoto,Masao Hosokawa +10 more
TL;DR: On the basis of a retrospective study of patients who underwent endoscopic resection for T1 CRC, those with tumors with only submucosal invasion are at low risk for cancer recurrence, however, patients with other high-risk tumor features have greater risks forcancer recurrence and benefit from subsequent surgery.
Journal ArticleDOI
Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
Katsuhiko Nosho,Hisayoshi Igarashi,Masanori Nojima,Miki Ito,Reo Maruyama,Shinji Yoshii,Takafumi Naito,Yasutaka Sukawa,Masashi Mikami,Wakana Sumioka,Eiichiro Yamamoto,Sei Kurokawa,Yasushi Adachi,Hiroaki Takahashi,Hiroyuki Okuda,Takaya Kusumi,Masao Hosokawa,Masahiro Fujita,Tadashi Hasegawa,Kenji Okita,Koichi Hirata,Hiromu Suzuki,Hiroyuki Yamamoto,Yasuhisa Shinomura +23 more
TL;DR: In this paper, the authors identify a relationship between specific miRNA molecules and BRAF mutation in colorectal cancers and serrated lesions and demonstrate that miR-31 inhibitor decreased cell invasion and proliferation.
Journal ArticleDOI
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Kohei Shitara,Kimio Yonesaka,Tadamichi Denda,Kentaro Yamazaki,Toshikazu Moriwaki,Masahiro Tsuda,Toshimi Takano,Hiroyuki Okuda,Tomohiro Nishina,Kazuko Sakai,Kazuto Nishio,Shoji Tokunaga,Takeharu Yamanaka,Narikazu Boku,Ichinosuke Hyodo,Kei Muro +15 more
TL;DR: Second‐line FOLFIRI plus panitumumab and FOL FIRI plus bevacizumab showed a similar efficacy in patients with WT KRAS exon 2 mCRC and RAS and BRAF mutation in ctDNA could be a negative predictive marker for panitUMumab.
Journal ArticleDOI
Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
Hisayoshi Igarashi,Hiroyoshi Kurihara,Kei Mitsuhashi,Miki Ito,Hiroyuki Okuda,Shinichi Kanno,Takafumi Naito,Shinji Yoshii,Hiroaki Takahashi,Takaya Kusumi,Tadashi Hasegawa,Yasutaka Sukawa,Yasutaka Sukawa,Yasushi Adachi,Kenji Okita,Koichi Hirata,Yu Imamura,Yoshifumi Baba,Kohzoh Imai,Hiromu Suzuki,Hiroyuki Yamamoto,Katsuhiko Nosho,Yasuhisa Shinomura +22 more
TL;DR: High miR-31-5p expression was associated with shorter PFS in patients with CRC treated with anti-EGFR therapeutics, suggesting that it may be a useful and additional prognostic biomarker for anti- EGFR therapy.